T. Rowe Price Associates’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-320,461
| Closed | -$16.6M | – | 3046 |
|
|
2022
Q3 | $16.6M | Buy |
320,461
+10,332
| +3% | +$534K | ﹤0.01% | 960 |
|
|
2022
Q2 | $7.69M | Sell |
310,129
-55,505
| -15% | -$1.38M | ﹤0.01% | 1355 |
|
|
2022
Q1 | $9.17M | Sell |
365,634
-1,789
| -0.5% | -$44.8K | ﹤0.01% | 1376 |
|
|
2021
Q4 | $13.4M | Sell |
367,423
-9,199
| -2% | -$335K | ﹤0.01% | 1360 |
|
|
2021
Q3 | $6.44M | Sell |
376,622
-68,276
| -15% | -$1.17M | ﹤0.01% | 1478 |
|
|
2021
Q2 | $5.96M | Buy |
444,898
+8,622
| +2% | +$115K | ﹤0.01% | 1479 |
|
|
2021
Q1 | $22.4M | Buy |
436,276
+33,148
| +8% | +$1.7M | ﹤0.01% | 1251 |
|
|
2020
Q4 | $25M | Buy |
403,128
+121,966
| +43% | +$7.55M | ﹤0.01% | 1164 |
|
|
2020
Q3 | $15.4M | Sell |
281,162
-351,795
| -56% | -$19.3M | ﹤0.01% | 1208 |
|
|
2020
Q2 | $36.4M | Buy |
632,957
+464,993
| +277% | +$26.8M | ﹤0.01% | 955 |
|
|
2020
Q1 | $6.75M | Buy |
167,964
+76,364
| +83% | +$3.07M | ﹤0.01% | 1290 |
|
|
2019
Q4 | $3.62M | Buy |
+91,600
| New | +$3.62M | ﹤0.01% | 1457 |
|
|
2018
Q2 | – | Sell |
-460,141
| Closed | -$6.26M | – | 2596 |
|
|
2018
Q1 | $6.26M | Buy |
+460,141
| New | +$6.26M | ﹤0.01% | 1399 |
|
|
2013
Q4 | – | Sell |
-646,800
| Closed | -$3.6M | – | 2520 |
|
|
2013
Q3 | $3.6M | Sell |
646,800
-24,100
| -4% | -$134K | ﹤0.01% | 1468 |
|
|
2013
Q2 | $9.49M | Buy |
+670,900
| New | +$9.49M | ﹤0.01% | 1263 |
|